Jazz Pharmaceuticals, Inc.
$243.59
$2.76 (+1.15%)
$241.76Day Range$244.36
Key Statistics
Market Cap
$15.81B
Shares Outstanding
64.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 1, 2007
Round Lot
100
Locale
US
Trading Data
Day Open
$242.93
Day High
$244.36
Day Low
$241.76
Volume
602.3K
VWAP
$243.18
Prev Close
$240.83
Transactions
--
Acc. Volume
--
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
PHARMACEUTICAL PREPARATIONSSIC 28342,890 employeesFIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN, D04 E5W7353-1-634-7800IPO Jun 1, 2007US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001232524
- Ticker Root
- JAZZ
- SIC Code
- 2834
About Jazz Pharmaceuticals, Inc. (JAZZ) Stock
Jazz Pharmaceuticals, Inc. (JAZZ) closed the 2026-09-16 session at $243.59, up 1.15% versus the previous close (+2.76). The stock opened at $242.93 and traded between $241.76 and $244.36 during that session. Session trading volume was 602K shares. The volume-weighted average price (VWAP) is $243.18.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Jazz Pharmaceuticals, Inc. has a market capitalization of $15.81 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. JAZZ is listed on the XNAS exchange. The company employs approximately 2,890 people. The recorded listing date is 2007-06-01.
On this page you can find market JAZZ stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.